Novel antipsychotics in schizophrenia

Bibliography

• DAVIS JM, SCHAFFER CB, KILLIAN GA: Important issues in the drug treatment of schizophrenia. Schizophr: Bull. (1980)6:70–87.
   Google Scholar
• BARNES TR, EDWARDS J: Antipsychotic Drugs and Their Side Effects. Academic Press, London (1993).
   Google Scholar
• FARDE L, WIESEL FA, HALLDIN C: Central dopamine-2 occupancy in schizophrenic patients treated with antipsychotic drugs. Arch. Gen. Psychiatry (1988)45:71–76.
   Google Scholar
• SEEMAN P: Handbook on Studies of Schizophrenia. GD Burrows, TR Norman, G Rubinstein (Eds), Elsevier, Amsterdam (1986).
   Google Scholar
• BREIER A, BUCHANAN JR, KIRKPATRICK B: Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am. Psychiatry (1994) 151:20–26.
   PubMed Web of Science ®Google Scholar
• KANE J, HONIGFELD G, SINGER J: Clozapine for the treatment resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry (1988)45:789–796.
   Google Scholar
• AUMBRICHT D, AMES D, WIRSHING WC: Predictors of response to clozapine in a long-term double blind treatment study. Schizophr. Res. (1997) 24:189. Expert Op/n. lnvestig. Drugs (2004) 13(4)323
   Google Scholar
• ROTH BL, SHEFFLER D, POTKIN SG: Atypical antipsychotic drug actions: Unitary or multiple mechanisms for `atypicality'? Clin. Neurosci. Research (2003) 31:108–117.
   Google Scholar
• •Articulates the latest arguments on the mechanism of antipsychotic action.
   Google Scholar
• KAPUR S, REMINGTON G: Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol. Psychiatry (2001) 50:873–883.
   PubMed Web of Science ®Google Scholar
• •See reference [8].
   Google Scholar
• KAPUR S, SEEMAN P: Does fast dissociation from the dopamine D(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am. Psychiatry (2001) 158:360–369.
   PubMed Web of Science ®Google Scholar
• KAPUR S, MAMO D: Half a century of antipsychotics and still a ce ntral role for dopamine D2 receptors. Prog.Neuropsychopharmacol Biol. Psychiatry 27:1081-1090.
   Google Scholar
• •See reference [8].
   Google Scholar
• MELTZER HY, LI Z, KANEDA Y, ICHIKAWA J: Serotonin receptors: their key role in drugs to treat schizophrenia. Frog. Neuropsychopharmacol Biol. Psychiatry (2003) 27:1159–1172.
   PubMed Web of Science ®Google Scholar
• •See reference [8].
   Google Scholar
• ABI-DARGHAM A: Recent evidence for dopamine abnormalities iin schizophrenia. Eur. Psychiatry(2002) 17:341–347.
   Web of Science ®Google Scholar
• ••About the modified dopamine hypothesisof the pathophysiology of schizophrenia.
   Google Scholar
• EKESBO A, ANDREN PE, GUNNE LM, TEDROFF J: (-)-0SU 6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinson's disease. Neuroreport (1997) 8:2567–2570.
   PubMed Web of Science ®Google Scholar
• EKESBO A, TORSTENSON R, HART VIG P et al.: Effects of the substituted (S)-3-phenylpiperidine (-)-0SU6162 on PET measurements of [11C] SCH23390 and [11C] raclopride binding in primate brains. Neuropharmacology (1999) 38:331–338.
   Google Scholar
• TEDROFF J, EKESBO A, SONESSON C, WATERS N, CARLSSON A: Long-lasting improvement following (-)-0SU6162 in a patient with Huntingdon's disease. Neurology(1999) 53: 1605-1606.
   Google Scholar
• TEDROFF J, TORSTENSON R, HART VIG P et al.: Effects of the substituted (S)-3-phenylpiperidine (-)0SU6162 on PET measurements in subhuman primates: evidence for tone-dependent normalization of striatal dopaminergic activity. Synapse (1998) 28:280–287.
   Google Scholar
• FETSKO LA, XU R, WANG Y: Alterations in D1/D2 synergism may account for enhanced stereotypy and reduced climbing in mice lacking dopamine D2L receptor. Brain Res. (2003) 967:191–200.
   PubMed Web of Science ®Google Scholar
• MILLAN MJ, SCHREIBER R, DEKEYNE A et al: S 16924 ((R) 2 (1 [2 (,3-dihydro-benzo [1,4] dioxin-5-yloxy)-ethyllpyrrolidin 3y1) 1 (4 fluoro-pheny1)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)(1A) agonist properties: II. Functional profile in comparison to clozapine and haloperidol. Pharmacol Exp. Ther. (1998) 286:1356–1373.
   PubMed Web of Science ®Google Scholar
• ELLENBROEK BA, LIEGEOIS J-F: JL 13, an atypical antipsychotic: a preclinical review. CNS Drug Rev (2003) 9:41–56.
   PubMedGoogle Scholar
• LIEGEOIS J-F, BRUHWYLER J, HENDRICK JC, DELARGE J, LEGROSS JJ, DAMES J: Minimal effects of JL 13, a pyridobenzoxazepine derivative with an antipsychotic potential, on circulating prolactin levels in male rats. NeuroscL Lett. (2002) 319:49–52.
   PubMed Web of Science ®Google Scholar
• LERICHE L, SCHWARTZ JC, SOKOLOFF P: The dopamine D3 receptor mediates locomotor hyperactivity induced by NMDA blockade. Neuropharmacology (2003) 45:174–181.
   PubMed Web of Science ®Google Scholar
• JOYCE JN: Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol TheL (2001) 90:231–259.
   PubMed Web of Science ®Google Scholar
• TEJEDOR-REAL P, FAUCON BIGUET N, DUMAS S, MALLET J: Tyrosine hydroxylase mRNA and protein are down-regulated by chronic clozapine in both the mesocorticolimbic and nigrostriatal systems. Neurosci. Research (2003) 72:105–115.
   Web of Science ®Google Scholar
• MORTIMER AM, BARNES TRE: Serotonergic Mechanisms in Antipsychotic Treatment. Marcel Dekker, Inc., New York (1996):311–330.
   Google Scholar
• DEAN B: The cortical serotonin2A receptor and the pathology of schizophrenia: a likely accomplice. Neurochem. (2003) 85:1–13.
   PubMed Web of Science ®Google Scholar
• •On the role of 5-HT in the pathophysiology of schizophrenia.
   Google Scholar
• YAN Z: Regulation of GABAergic inhibition by serotonin signalling in prefrontal cortex: Molecular mechanisms and functional implications. Mol Neurobiol (2002) 26:203–216.
   PubMed Web of Science ®Google Scholar
• MA J, YE N, LANGE N, COHEN BM:Dynorphinergic GABA neurons are a target of both typical and atypical antipsychotic drugs in the nucleus accumbens shell, central amygdaloid nucleus and thalamic central medial nucleus. Neuroscience (2003) 121:991–998.
   PubMed Web of Science ®Google Scholar
• ANDREE B, HALLDIN C, VRIIMOED-DE VRIES M, FARDE L: Central 5-HTA and D2 dopamine receptor occupancy after sublingual administration of ORG 5222 in healthy men. Psychopharmacology (1997) 131:339–345.
   PubMed Web of Science ®Google Scholar
• RICHELSON E, SOUDER T: Binding of antipsychotic drugs to human brain receptors: focus on new generation compounds. Life Sci. (2000) 68:29–39.
   PubMed Web of Science ®Google Scholar
• NAGAI T, NODA Y, UNA T et al: Effect of AD-5423 on animal models of schizophrenia: phencyclidine-induced behavioural changes in mice. Neuroreport (2003) 14:269–272.
   PubMed Web of Science ®Google Scholar
• SHIWA T, AMANO T, MATSUBAY-ASHI H, SEKI T, SASA M, SAKAI N: Perospirone, a novel antipsychotic agent, hyperpolarizes rat dorsal raphe neuron via 5-HT1A receptor.' Pharmacol Sci. (2003) 93:114–117.
   PubMed Web of Science ®Google Scholar
• TOGO T, ISEKI E, SHOJI M et al: Prolactin levels in schizophrenic patients receiving perospirone in comparison to risperidone. I Pharmacol ScL (2003) 91:259–262.
   PubMed Web of Science ®Google Scholar
• TALAGA P, MATAGNE A, KLITGAARD H: Pharmacological evaluation of a diarylmethylene-piperidine derivative: A new potent atypical antipsychotic? Bioorg. Med. Chem. Letters (2001) 11:1313–1316.
   PubMed Web of Science ®Google Scholar
• KAWASHIMA N, FUNAKOSHI T, OMURA T, CHAKI S, KARMEO K, OKAYAMA S: Neuropharmacological profiles of a novel atypical antipsychotic, NRA0562, in rats. Eur.j Pharmacol (2001) 423:27–33.
   PubMed Web of Science ®Google Scholar
• FUNAKOSHI T, CHAKI S, KAWASHIMA N et al: In vitro and M vivo pharmacological profile of 542- [4-(6-fluoro-1H-indole-3-yl)piperidin-1-yl] ethyl} 4 (4 fluorophenyl) thiazo le- 2-carboxylic acid amide (NRA0562), a novel and putative atypical antipsychotic. Life Sci. (2002) 71:1371–1384.
   PubMed Web of Science ®Google Scholar
• TAKAMORI K, FUNAKOSHI T, HIROTA S, CHAKI S, KAMEO K: 324Expert Op/n. lnvestig. Drugs (2004) 13(4) Antipsychotic profile of 5 {2 [4 (6 fluoro 1H-indole-3-Apiperidin-1-yl]ethyll 4 (4 fluorophenyl)thiazole-2-carboxylic acid amide (NRA0562) in rats. Life Sci. (2002) 71:947–952.
   Google Scholar
• CAMPIANI G, BUTINI S, GEMMA S et al.: Pyrrolo [1, 3]benzothiazepine-basedatypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies. Med. Chem. (2002) 45:344–359.
   Google Scholar
• ORJALES A, MOSQUERA R, TOLEDO A, PUMAR C, LABENGA L, INNERARITY A: New 3-benzisothiazoly1 and 3-benzisoxazolylpiperazine derivatives with atypical antipsychotic binding profile. Eur.j Med. Chem. (2002) 37:721–730.
   PubMed Web of Science ®Google Scholar
• CHUNG IW, MOORE NA, OH WK et al.: Behavioural pharmacology of polygalasaponins indicates potential antipsychotic efficacy. Pharmacol Biochem. Behav. (2002) 71:191–195.
   PubMed Web of Science ®Google Scholar
• JIN G-Z, ZHU Z-T, FU Y: (-)-Stepholidine: a potential novel antipsychotic drug with dual D1 receptor agonist and D2 receptor antagonist actions. Trends Pharmacol Sci. (2002) 23:4–7.
   PubMed Web of Science ®Google Scholar
• ABEKAWA T, HONDA M, ITO K, KOYAMA T: Effects of NRA0045, a novel potent antagonist at dopamine D4, 5-HT2A, and al adrenaline receptors, and NRA0160, a selective D4 receptor antagonist, on phencylidine-induced behaviour and glutamate release in rats. Psychopharmacology (2003) 169:247–256.
   PubMed Web of Science ®Google Scholar
• ICHIKAWA J, ISHII H, BONACCORSO S, FOWLER WL, O'LANGHLIN IA, MELTZER HY: 5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT lAreceptor activation: possible mechanism of atypical antipsychotic-induced dopamine release. Neurochem. (2001) 76:1521–1531.
   PubMed Web of Science ®Google Scholar
• FERRE S, CIRUELA F, WOODS AS et al: Glutamate mG1u5-adenosine A2A-dopamine D2 receptor interactions in the striatum. Implications for drug therapy in neuro-psychiatric disorders and drug abuse. Curc Med. Chem. (2003) 3:1–26.
   Google Scholar
• NEWMAN-TANCREDI A, RIVET JM, CUSSAC D et al.: Comparison of hippocampal G protein activation by 5-HT1p, receptor agonists and the atypical antipsychotics clozapine and S16924. Naunyn Schmiedebergs Arch. Pharmacol (2003) 368:188–199.
   PubMed Web of Science ®Google Scholar
• RIGDON GC, NORMAN MH, COOPER BR et al.: 1192U90 in animal tests that predict antipsychotic efficacy, anxiolysis, and extrapyramidal side effects. Neuropsychopharmacology (1996) 15:231–242.
   PubMed Web of Science ®Google Scholar
• DEPOORTERE R, BOULAY D, PERRAULT G et al: 55R181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioural propfile predictive of an atypical antipsychotic activity. Neuropsychopharmacology (2003) 28:1889–1902.
   Google Scholar
• BENGTSSON HJ, KULLBERG A, MILLAN MJ, HJORTH S: The role of 5-HT(1A) autoreceptors and aradrenoceptors in the modulation of 5-HT release - III. Clozapine and the novel putative antipsychotic S 16924. Neuropharmacology (1998) 37:349–356.
   Google Scholar
• MILLAN MJ, SCHREIBER R, MONNEYRON S et al.: S-16924, a novel, potential antipsychotic with marked serotoninlA agonist properties. IV. A drug discrimination comparison with clozapine. .1. Pharmacol Exp. Ther. (1999) 289:427–436.
   Google Scholar
• MILLAN MJ, GOBERT A, NEWMAN-TANCREDIT A et al.: S 16924 ((R)-2-(1-[2(3-dihydro-benzo [1,4] dioxin-5-yloxy)-ethyllpyrrolidin 3y1) 1 (4 fluoro-pheny1)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT) (1A) agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol. Pharmacol Exp. Ther. (1998) 286:1341–1355.
   Google Scholar
• MILLAN MJ, BROCCO M, GOBERT A, SCHREIBER R, DEKEYNE A: S-16924, a novel potential antipsychotic with marked serotonin (1A) agonist properties: III. Amdolytic actions in comparison with clozapine and haloperidol. Pharmacol Exp. Ther. (1999) 288:1002–1014.
   PubMed Web of Science ®Google Scholar
• WOLF W: DU-127090. Curc Opin. Investig. Drugs (2003) 4:72–76.
   PubMedGoogle Scholar
• HAMEG A, BAYLE F, NUSS P, DUPUIS P, GARAY RP, DIP M: Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine versus serotonin receptor subtypes. Biochem. Pharmacol (2003) 65:435–440.
   PubMed Web of Science ®Google Scholar
• BONACCORSO S, MELTZER HY, LI Z, DAI J, ALBOSZTA AR, ICHIKAWA J: 5R46349-B, a 5-HT2Aacreceptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex. Neuropsychopharmacology (2002) 27:430–441.
   PubMed Web of Science ®Google Scholar
• VAN HES R, SMIA P, STROOMER CN et al.: SLV310, a novel, potential antipsychotic, combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibition. Bioorg. Med. Chem. Letters (2003) 13:405–408.
   PubMed Web of Science ®Google Scholar
• PIETRAZEK M: Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms. Poi Pharmacol (2003) 55:133–154.
   Google Scholar
• •Glutamate- and 5-HT-mediated mechanisms in antipsychotic action.
   Google Scholar
• DEUTSCH SI, SCHARTZ BL, ROSSE RB, MASTROPAOLO J, MARVEL CL, DRAPALSKI AL: Adjuvant topiramate administration: a pharmacologic strategy for addressing NMDA hypofunction in schizophrenia. Clin. Neuropharmacol (2003) 26:199–206.
   PubMed Web of Science ®Google Scholar
• BREESE GR, KNAPP DJ, MOY SS: Integative role for serotonergic and glutamatergic receptor mechanisms in the action of NMDA antagonists: potential relationships to antipsychotic drug actions on NMDA antagonist responsiveness. NeuroscL Biobehav. Rev (2002) 26:441–455.
   PubMed Web of Science ®Google Scholar
• HANAOKA T, TOYODA H, MIZUNO T et al.: Alterations in NMDA receptor subunit levels in the brain regions of rats chronically administered typical or atypical antipsychotic drugs. Neurochem. Res. (2003) 28:919–924.
   PubMed Web of Science ®Google Scholar
• SCHMITT A, SCHMITT A, ZINK M et al.: Effects of long-term antipsychotic treatment oon NMDA receptor binding and gene expression of subunits. Neurochem. Res. (2003) 28:235–241.
   PubMed Web of Science ®Google Scholar
• NINAN I, JARDEMARK KE, WANG RY: Differential effects of atypical and typical antipsychotic drugs on N-methyl-D-aspartate- and electrically evoked responses in the pyramidal cells of the rat medial prefrontal cortex. Synapse (2003) 48:66–79.
   PubMed Web of Science ®Google Scholar
• LEVINE JB, MARTIN G, WILSON A, TREISTMAN SN: Clozapine inhibits isolated N-methyl-D-aspartate receptors expressed in xenopus oocytes in a subunit specific manner. NeuroscL Lett. (2003) 346:125–128.
   PubMed Web of Science ®Google Scholar
• JARDEMARK KE, AL J, NINAN I, WANG RY: Biphasic modulation of
   Google Scholar
• Expert Op/n. lnvestig. Drugs (2004) 13(4) NMDA-induced responses in pyramidal cells of the medial prefrontal cortex by Y-931, a potential atypical antipsychotic drug. Synapse (2001) 41:294–300.
   Google Scholar
• MINABE Y, HASHIMOTO K, SHIRAYA Y, ASHBY CR Jr: Effect of the acute and chronic administration of the putative atypical antipsychotic drug Y-931 (8-fluoro-12- (4-methylpiperazin-1-y6-6H-[1] benzothieno [2,36] [1,5] benzodiazepine maleate) on spontaneously active rat midbrain dopamine neurons: an in vivo electrophysiological study. Synapse (2004) 51:19–26.
   PubMed Web of Science ®Google Scholar
• SHIIGI Y, MAEDA J-I, YASUMATSU H,TANAKA H, CASEY DE: Effect of a novel potential atypical antipsychotic drug, Y-931, in producing dystonia in Cebus monkeys. Pharmacol Sci. (2003) 93:364–366.
   Web of Science ®Google Scholar
• MORIMOTO T, HASHIMOTO K, YASUMATU H et al.: Neuropharmacological profile of a novel potential atypical antipsychotic drug Y-931 (8-fluoro-12-(4-methylpiperazin-1-y6-6H-[1] benzothieno [2,3-6] [1,5] benzodiazepine maleate. Neuropsychopharmacology (2002) 26:456–467.
   PubMed Web of Science ®Google Scholar
• SCHMITT A, ZINK M, PETROIANN G et al: Decreased gene expression of glial and neuronal glutamate transporters after chronic antipsychotic treatment in rat brain. Neurosci. Lett. (2003) 347:81–84.
   PubMed Web of Science ®Google Scholar
• ADAMS BW, MOGHADDAM B: Effect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex. Biol. Psychiatry(2001) 50:750–757.
   PubMed Web of Science ®Google Scholar
• BAHR BA, BENDISKE J, BROWN OB et al.: Survival signaling and selective neuroprotection through glutamatergic transmission. Exp. Neural. (2002) 174:37–47.
   PubMed Web of Science ®Google Scholar
• GEYER MA, ELLENBROEK BA: Animal behavior models of the mechanisms underlying antipsychotic atypicality. Progc Neuro-Psychopharmacol Biol. Psychiatry (2003) 27:1071–1079.
   PubMed Web of Science ®Google Scholar
• •On the limitations of animal models in the development of atypical antipsychotics.
   Google Scholar
• JOHNSON SA, LUU NT, HERBST TA et al.: Synergistic interactions between ampakines and antipsychotic drugs. Pharmacol Exp. Ther. (1999) 289:392–397.
   PubMed Web of Science ®Google Scholar
• TAKAMORI K, HIROTA S, CHAKI S, TANAKA M: Antipsychotic action of selective group II metabotropic glutamate receptor agonist MGS0008 and MG50028 on conditioned avoidance responses in the rat. Life Sci. (2003) 73:1721–1728.
   PubMed Web of Science ®Google Scholar
• SWANSON CJ, SCHOEPP DD: The group II metabotropic glutamiate receptor agonist ( ) 2 oxa 4 aminobicyclo [3.1.0.] hexane-4, 6 - dicarboxylate (LY379268) and clozapine reverse phencyclidine-induced behaviours in monoamine-depleted rats. Pharmacol Exp. Ther. (2002) 303:919–927.
   Google Scholar
• KINNEY GG, BURNO M, CAMPBELL UC et al: Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. Pharmacol Exp. The]: (2003) 306:116–123.
   Google Scholar
• CORBETT R, ZHOU L, SORENSEN SM, MONDADORI C: Animal models of negative symptoms: M100907 antagonizes PCP-induced immobility in a forced swim test in mice. Neuropsychopharmacology (1999) 21:E211–E218.
   Google Scholar
• OVALLE S, ZAMANILLO D, ANDREU F, FARRE AJ, GUITART X: Fibroblast growth factor-2 is selectively modulated in the rat brain by E-5842, a preferential sigma-1 receptor ligand and putative atypical antipsychotic. Ear. NeuroscL (2001) 13:909–915.
   PubMed Web of Science ®Google Scholar
• MONROY X, ROMERO G, PEREZ MP, FARRE AJ, GUITART X: Decrease of adenylyl cyclase activity and expression by a sigmal receptor ligand and putative atypical antipsychotic. Neuroreport (2001) 12:1989–1992.
   PubMed Web of Science ®Google Scholar
• HARSING LG Jr, GACSALY I, SZABO Get al.: The glycine transporter - 1 inhibitors NFPS and Org 24461: a pharmacological study. Pharmacol Biochem. Behav. (2003) 74:811–825.
   Google Scholar
• KINNEY GG, SUR C, BURNO M et al.:The glycine transporter Type 1 inhibitor N- [3-(4'-fluoropheny0-3- (4'-phenylphenoxy)propyllsarcosine potentiates NMDA receptor-mediated responses in vivo and produces and antipsychotic profile in rodent behaviour. Neurosci. (2003) 23:7586-7591. ao. BRODY SA, GEYER MA, LARGE CH: Lamotrigine prevents ketamine but not amphetamine-induced deficits in prepulse inhibition in mice. Psychopharmacology (2003) 169:240–246.
   Google Scholar
• KALKMAN HO, LOETSCHER E: GAD67: the link between the GABA-deficit hypothesis and the dopaminergic- and glutamatergic theories of psychosis. Neural Transm. (2003) 110:803–812.
   PubMed Web of Science ®Google Scholar
• •A synthesis of glutamate, dopamine and GABA in the pathophysiology of schizophrenia.
   Google Scholar
• MIRZA NR, PETERS D, SPARKS RG: Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS Drug Rev (2003) 9:159–186.
   PubMedGoogle Scholar
• ICHIKAWA J, CHUNG Y-C, LIZ, DAI J,MELTZER HY: Choliergic modulation of basal and amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleaus accumbens. Brain Res. (2002) 958:176–184.
   PubMed Web of Science ®Google Scholar
• RASMUSSEN T, FINK-JENSEN H, SAUERBERG P et al.: The muscarinic receptor agonist BuTAC, a novel potential antipsychotic, does not impair learning and memory in mouse passive avoidance. Schizoplm Res. (2001) 49:193–201.
   PubMed Web of Science ®Google Scholar
• BYMASTER FP, FELDER CC, TZAVARA E, NOMIKOS GG, CALLIGARO DO, MCKINZIE DL: Muscarinic mechanisms of antipsychotic atypicality. Frog. Neuropsychopharmacol Biol. Psychiatry (2003) 27:1125–1143.
   PubMed Web of Science ®Google Scholar
• •Acetylcholine and antipsychotic action.
   Google Scholar
• ICHIKAWA J, LI Z, DAI J, MELTZER HY: Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rate medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res. (2002) 956:349–357.
   PubMed Web of Science ®Google Scholar
• SIMOSKYJK, STEVENS KE, ADLER LE, FREEDMAN R: Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism. Psychopharmacology (2003) 165:386–396.
   PubMed Web of Science ®Google Scholar
• AMARGOS-BOSCH M, ADELL A, BORTOLOZZI A, ARTIGAS F: Stimulation of aradrenoceptors in the rat medial prefrontal cortex increases the loca. in vivo 5-hydroxytryptamine release: reversal by antipsychotic drugs. Neurochem. (2003) 87:831–842.
   Google Scholar
• SVENSSON TH: a-Adrenoceptor modulation hypothesis of antipsychotic atypicality. Frog. Neuropsychopharmacol Biol. Psychiatry (2003) 27:1145–1158.
   PubMed Web of Science ®Google Scholar
• GONZALEZ-GOMEZ JC, SANTANA L, URIARTE E et al.: New arylpiperazine
   Google Scholar
• Expert Op/n. Investig. Drugs (2004) 13(4) derivatives with high affinity of aiA, D2 and 5-HT2A receptors. Bioorg. Med. Chem. Letts. (2003) 13:175–178.
   Google Scholar
• BALLET, PERREGAARD J, LARSEN AK et al.: Synthesis and structure-affinity relationship investigations of 5-aminomethyl and 5-carbamoyl analogues of the antipsychotic sertindole. A new class of selective al adrenoceptor antagonists. Bioorg. Med. Chem. (2003) 11:1065–1078.
   Google Scholar
• DEVOTO P, FLORE G, VACCA G et al.: Co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex induced by clozapine, the prototype atypical antipsychotic. Psychopharmacology (2003) 167:79–84.
   PubMed Web of Science ®Google Scholar
• KHALIFA AE: Zuclopenthixol facilitates memory retrieval in rats: possible involvement of noradrenergic and serotonergic mechanisms. Pharmacol Biochem. Behav. (2003) 75:755–762.
   PubMed Web of Science ®Google Scholar
• CANALS M, MARCELLINO D, FANELLI F et al.: Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer.' Biol. Chem. (2003) 278:46741–46749.
   Google Scholar
• ANDERSEN MB, FUXE K, WERGE T, GERLACH J: The adenosine A2A receptor agonist CGS 21680 exhibits antipsychotic-like activity in Cebus apella monkeys. Behav. Pharmacol (2002) 13:639–644.
   PubMed Web of Science ®Google Scholar
• WARDAS J, KONIECZNY J, PIETRASZEK M: Influence of CGS 21680, a selective adenosine A2A agonist, on the phencyclidine-induced sensorimotor gating deficit and motor behaviour in rats. Psychopharmacology (2003) 168:299–306.
   PubMed Web of Science ®Google Scholar
• BAT 0, CHLAN-FOURNEY J, BOWEN R, KEEGAN D, LI X-M: Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. Neurosci. Res. (2003) 71:127–131.
   Web of Science ®Google Scholar
• CHLAN-FOURNEY J, ASHE P, NYLEN K, JUORIO AV, LI X-M: Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration. Brain Res. (2002) 954:11–20.
   PubMed Web of Science ®Google Scholar
• OVALLE S, ANDREU F, PEREZ MP, ZAMANILLO D, GUITART X: Effect of the novel sigma ligand and putative atypical antipsychotic E-5842 on BDNF mRNA expression in the rat brain. Neuroreport (2002)13:2345-2348. loft FUMAGALLI F, MOLTENI R, ROCERI M et al.: Effect of antipsychotic drugs on brain-derived neurotrophic factor expression under reduced N-methyl-D-aspartate receptor activity. NeuroscL Research (2003) 72:622–628.
   Google Scholar
• BAT 0, WET Z, LU W et al.: Protective effects of atypical antipsychotic drugs on PC12 cells after serum withdrawal. Neurosci. Res. (2002) 69:278–283.
   Google Scholar
• QING H, XU H, WET Z, GIBSON K, LI X-M: The ability of atypical antipsychotic drugs versus haloperidol to protect PC12 cells against MPRLinduced apoptosis. Eur: Neurosci. (2003) 17:1563–1570.
   PubMed Web of Science ®Google Scholar
• DOBNER PR, DEUTCH AY, FADEL J: Neurotensin: dual roles in psychostimulant and antipsychotic drug responses. Life Sci. (2003) 73:801–811.
   PubMed Web of Science ®Google Scholar
• LIPSKA BK, LERMAN DN, KHAING ZZ, WEICKERT CS, WEINBERGER DR: Gene expression in dopamine and GABA systems in an animal model of schizophrenia: effects of antipsychotic drugs. Eui: I Neurosci. (2003) 18:391–402.
   PubMed Web of Science ®Google Scholar
• CACEDA R, KINKEAD B, NEMEROFF CB: Do neurotensin receptor agonists represent a novel class of antipsychotic drugs? Sem.Clin. Neuropsychiamy (2003) 8:94–108.
   Google Scholar
• SHILLING PD, RICHELSON E, FEIFEL D: The effects of systemic NT69L, a neurotensin agonist, on baselline and drug-disrupted prepulse inhibition. Behav. Brad) Res. (2003) 143:7–14.
   PubMed Web of Science ®Google Scholar
• BOULES M, McMAHON B, WANG R et al.: Selective tolerance to the hypothermic and anticataleptic effects of a neurotensin analog that crosses the blood-brain barrier. Brad) Res. (2003) 987:39–48.
   PubMed Web of Science ®Google Scholar
• GARCIA-OSTA A, FRECHILLA D, DEL RIO J: Reduced basal an phencyclidine-induced expression of heat shock protein-70 in rat prefrontal cortex by the atypical antipsychotic abaperidone. Frog. Neuropsychopharmacol Biol. Psychiatry (2003) 27:31–36.
   PubMed Web of Science ®Google Scholar
• MAHADIK SP, EVANS DR: Is schizophrenia a metabolic brain disorder? Membrane phospholipid dysregulation and its therapeutic implications. Psychiam Clio. North Am. (2003) 26:85–102.
   PubMed Web of Science ®Google Scholar
• •The lipid hypothesis of schizophrenia pathophysiology.
   Google Scholar
• ARVINDAKSHAN M, SITASAWAD S, DEBSIKDAR V et al: Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenic patients. Biol. Psychiatry (2003) 53:56–64.
   PubMed Web of Science ®Google Scholar
• EVANS DR, PARIKH VV, KHAN MM, COUSSONS C, BUCKLEY PF, MAHADIK SP: Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins Leukot. Essent. Fatg Acids (2003) 69:393–399.
   PubMed Web of Science ®Google Scholar
• SCHMITT A, MARAS A, PETROIANU G, BRAUS DF, SCHEUER L, GATTAZ WE: Effects of antipsychotic treatment on membrane phospholipid metabolism in schizophrenia. Neural. (2001) 248:1081–1091.
   Google Scholar
• TAVARES JRH, YACUBIAN J, TALIB LL, BARBOSA NR, GATTAZ WF: Increased phospholipase A2 activity in schizophrenia with absent response to niacin. Schizophi: Res. (2003) 61:1–6.
   PubMed Web of Science ®Google Scholar
• EMSLEY RA, MYBURGH C, OOSTHUIZEN P, VAN RENSBURG SJ: Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am. .1. Psychiatry (2002) 159:1596–1598.
   Google Scholar
• THOMAS EA, COPOLOV DL, SUTCLIFFE JG: From pharmacotherapy to pathophysioilogy: emerging mechanisms of apolipoprotein D in psychiatric disorders. Curr. Mol Med. (2003) 3:408–418.
   PubMed Web of Science ®Google Scholar
• KHAN MM, PARIKH VV, MAHADIK SP: Antipsychotic drugs differentially modulate apolipoprotein D in rat brain. Neurochem. (2003) 86:1089–1100.
   PubMed Web of Science ®Google Scholar
• CHEN Y, BRUNAUER LS, CHU FC, HELSELCM, GEDDE MM, HUESTIS WH: Selective amphipathic nature of chlorpromazine binding to plasma membrane bilayers. Biochim. Biophys. Acta (2003) 1616:95–105.
   PubMed Web of Science ®Google Scholar
• LIDOW MS: Calcium signalling dysfunction in schizophrenia: a unifying approach. Brad) Res. Rev (2003) 43:70–84.
   PubMed Web of Science ®Google Scholar
• •The calcium signalling hypothesis of schizophrenia pathophysiology.
   Google Scholar
• SCZEKAN SR, STRUMWASSER F: Antipsychotic drugs block 1P3-dependent
   Google Scholar
• Expert Op/n. Investig. Drugs (2004) 13(4) Ca2+ release from rat brain microsomes. Biol. Psychiatry(1996) 40:497–502.
   Google Scholar
• NINAN I, JARDEMARK KE, LIANG X, WANG RY: Calcium/calmodulin-dependent kinase II is involved in the facilitating effect of clozapine on NMDA-and electrically evoked responses in the medial prefrontal cortical pyramidal cells. Synapse (2003) 47:285–294.
   PubMed Web of Science ®Google Scholar
• ANGELUCCI F, GRUBER SH, MATHE AA: A pilot study of rat brain regional distribution of calcitonin, katacalcin and calcitonin gene-related peptide before and after antipsychotic treatment. Neuropeptides (2001) 35:285–291.
   PubMed Web of Science ®Google Scholar
• WILLIAMS M: Genome-based drug discovery: prioritizing disease-susceptibility/ disease-associated genes as novel drug targets for schizophrenia. Can: Opin. Investig. Drugs (2003) 4:31–36.
   PubMedGoogle Scholar
• •Explains genome-based approaches to drug discovery.
   Google Scholar
• KONTKANEN 0, TORONEN P, LAKSO M, WONG G, CASTREN E: Antipsychotic drug treatment induces differential gene expression in the rat cortex. .1. Neurochem. (2002) 83:1043–1053.
   Google Scholar
• XU R, HRANILOVIC D, FETSKO LA, BUCAN M, WANG Y: Dopamine D25 and D2L receptors may differentially contribute to the actions of antipsychotic and psychotic agents in mice. Ma Psychiatry(2002) 7:1075–1082.
   Google Scholar
• LERER B: Predicting drug response from genetic markers moves ever closer. Frog. Neurol Psychiatry (2004) 8:26–30.
   Google Scholar
• •See reference [122].
   Google Scholar
• GUNTHER EC, STONE DJ, GERWIEN RW, BENTO P, HEYES MP: Prediction of clinical drug efficacy by classification of drug-induced genomic expressioin profiles in vitro. Proc. Nat. Acad. Sci. USA (2003) 100:9608–9613.
   PubMed Web of Science ®Google Scholar
• •See reference [122].
   Google Scholar
• LANE HY, CHANG Y-C, HUANG C-L, CHANG W-H: Refining pharmacogenetic research in schizophrenia: control for patient-related variables. Drug Dev. Res. (2003) 60:164–171.
   Web of Science ®Google Scholar
• •See reference [122].
   Google Scholar
• GOODNICK PJ, JERRY JM: Aripiprazole: profile on efficacy and safety. Expert Opin. Pharmacother: (2002) 3:1773–1781.
   Google Scholar
• •Articulates the actions of aripirazole and other partial dopamine agonists in the treatment of schizophrenia.
   Google Scholar
• TAMMINGA CA: Partial dopamine agonists in the treatment of psychosis. J. Neural Transm. (2002) 109:411–420.
   PubMed Web of Science ®Google Scholar
• •See reference [128].
   Google Scholar
• LAWLER CP, PRIOLEAN C, LEWIS MM et al: Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology (1999) 20:612–627.
   PubMed Web of Science ®Google Scholar
• STAHL SM: Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. I Clin. Psychiatry (2001) 62:923–924.
   PubMed Web of Science ®Google Scholar
• STAHL SM: Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part rGoldilocks' actions at dopamine receptors. j Clin. Psychiatry (2002) 62:841–842.
   Web of Science ®Google Scholar
• MATSUBAYASHI H, AMANO T, SASA M: Inhibition by aripiprazole of dopaminergic inputs to striatal neurons from substantia nigra. Psychophannacologia (1999) 146:139–143.
   PubMed Web of Science ®Google Scholar
• NAKAI S, HIROSE T, UWAHODO Y et al.: Diminished catalepsy and dopamine metabolism distinguish aripirazole from haloperidol or risperidone. Eur: Phannacol (2003) 472:89–97.
   PubMed Web of Science ®Google Scholar
• SUGIYAMA A, SATOH Y, HASHIMOTO K: In vivo canine model comparison of cardiohemodynamic and electrophysiological effects of a new antipsychotic drug aripiprazole (OPC-14597) to haloperidol. Toxicol Appl. Phannacol (2001) 173:120–128.
   PubMed Web of Science ®Google Scholar
• PIGOTT TA, CARSON WH, SAHA AR et al.: Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia. j Clin. Psychiatry (2003) 64:1048–1056.
   PubMed Web of Science ®Google Scholar
• BOWLES TM, LEVIN GM: Aripiprazole: a new atypical antipsychotic drug. Ann. Phannacother. (2003) 37:687–694.
   PubMed Web of Science ®Google Scholar
• POTKIN SG, SAHA AR, KUJAWA MJ et al.: Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone versus placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry (2003) 60:681–690.
   PubMed Web of Science ®Google Scholar
• TAYLOR DM: Aripiprazole: a review of its pharmacology and clinical use. Int. j Clin. Frac. (2003) 547:49–54.
   Google Scholar
• RIEDEL M, STRASSNIG M, KUHN K-U, MULLER N, MOLLER H-J: Aripiprazole - can a new pharmacological mode of action lead to a new quality in the treatment of schizophrenia? Psychopharmakotherapie (2003) 10:46–54.
   Web of Science ®Google Scholar
• CASEY DE, CARSON WH, SAHA AR et al.: Switching patients to aripiprazole from other antipsychotic agents: a muticenter randomized study. Psychopharmacology (2003) 166:391–399.
   PubMed Web of Science ®Google Scholar
• KEPPEL HESSELINK JM: Iloperidone: Hoechst Marion Roussel, Inc. ID drugs 2:584–590 (1999).
   PubMedGoogle Scholar
• JAIN KK: An assessment of iloperidone for the treatment of schizophrenia. Expert Opin. Investig. Drugs (2000) 9:2935–2943.
   PubMed Web of Science ®Google Scholar
• SUMIYOSHI T, JAYATHILAKE K, MELTZER HY: A comparison of two doses of melperone, an atypical antipsychotic drug, in the treatment of schizophrenia. Schizophr: Res. (2003) 62:65–72.
   PubMed Web of Science ®Google Scholar
• MELTZER HY, SUMIYOSHI T, JAYATHILAKE K: Melperone in the treatment of neuroleptic-resistant schizophrenia. Psychiatry Res. (2001) 105:201–209.
   PubMed Web of Science ®Google Scholar
• SUMIYOSHI T, JAYATHILAKE K, MELTZER HY: The effect of melperone, an atypical antipsychotic drug, on cognitive function in schizophrenia. Schizophr: Res. (2003) 59:7–16.
   PubMed Web of Science ®Google Scholar
• REMINGTON G: Understanding antipsychotic `atypicality': a clinical and pharmacological moving target. I Psychiatry Neurosci. (2003) 28:275–284.
   PubMed Web of Science ®Google Scholar
• •A review of what is meant by atypicality alongside an account of recent developments.
   Google Scholar
• VOLZ HP, MOLLER HJ, GEREBTZOFF A, BISCHOFF S: Savoxepine versus haloperidol: reasons for a failed clinical trial in patients with an acute episode of schizophrenia. Eur: Arch. Psychiatry Clin. Neurosci. (2002) 252:76–80.
   PubMed Web of Science ®Google Scholar
• KIRAN B, SRIVASTAVA VK, KUMAR A: Synthesis and antipsychotic activity of some new phenothiazine derivatives. Indian Drugs (2002) 39:234–238.
   Google Scholar
• BARNETT D: Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. National Institute for Clinical Excellence. Technology Appraisal Guidance, London. (2002) 43 (report)
   Google Scholar
• MORTIMER AM: Levels of explanation — symptoms, neuropsychological deficit and morphological abnormalities in schizophrenia. Br: J. Psychiatry (1994) 24:541–545.
   Google Scholar
• ••The author's theoretical paper articulatingthe fragmented nature of research into schizophrenia. Affiliation Ann M Mortimer BSc, MBChB, MMedSc, FRCPsych, MD Foundation Chair in Psychiatry, Department of Psychiatry, University of Hull, Southcoates Annexe, Cottingham Road, Hull, HUG 7RX, UK Tel: +44 (0) 1482 464565; Fax: +44 (0) 1482 466966
   Google Scholar